Filing Details
- Accession Number:
- 0001214659-21-006762
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-21 17:12:19
- Reporting Period:
- 2021-06-18
- Accepted Time:
- 2021-06-21 17:12:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1576263 | Mirati Therapeutics Inc. | MRTX | Pharmaceutical Preparations (2834) | 462693615 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1579824 | M Charles Baum | C/O Mirati Therapeutics Inc. 3545 Cray Court San Diego CA 92121 | President & Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-06-18 | 40,000 | $8.49 | 152,714 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-06-18 | 4,816 | $164.07 | 147,898 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-06-18 | 13,338 | $164.90 | 134,560 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-06-18 | 20,823 | $166.07 | 113,737 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-06-18 | 1,023 | $166.73 | 112,714 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2021-06-18 | 40,000 | $0.00 | 40,000 | $8.49 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 47,204 | 2017-05-09 | 2022-11-12 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020.
- This transaction was executed in multiple trades at prices ranging from $163.45 to $164.41. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $164.47 to $165.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $165.53 to $166.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $166.53 to $166.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Billionaire Hedge Funds
